AU2012216632A1 - Crystallization Method and Bioavailability - Google Patents

Crystallization Method and Bioavailability

Info

Publication number
AU2012216632A1
AU2012216632A1 AU2012216632A AU2012216632A AU2012216632A1 AU 2012216632 A1 AU2012216632 A1 AU 2012216632A1 AU 2012216632 A AU2012216632 A AU 2012216632A AU 2012216632 A AU2012216632 A AU 2012216632A AU 2012216632 A1 AU2012216632 A1 AU 2012216632A1
Authority
AU
Australia
Prior art keywords
bioavailability
crystallization method
crystallization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2012216632A
Other versions
AU2012216632B2 (en
Inventor
Miranda Cheney
Mazen Hanna
Raymond K. Houck
Ning SHAN
David Weyna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thar Pharma LLC
Original Assignee
Thar Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/023427 external-priority patent/WO2011097269A1/en
Application filed by Thar Pharma LLC filed Critical Thar Pharma LLC
Publication of AU2012216632A1 publication Critical patent/AU2012216632A1/en
Application granted granted Critical
Publication of AU2012216632B2 publication Critical patent/AU2012216632B2/en
Priority to AU2016219653A priority Critical patent/AU2016219653B2/en
Assigned to GRUNENTHAL GMBH reassignment GRUNENTHAL GMBH Request for Assignment Assignors: THAR PHARMACEUTICALS, INC.
Assigned to THAR PHARMA, LLC reassignment THAR PHARMA, LLC Request for Assignment Assignors: GRUNENTHAL GMBH
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

AU2012216632A 2010-02-06 2012-09-04 Crystallization Method and Bioavailability Ceased AU2012216632B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2016219653A AU2016219653B2 (en) 2010-02-06 2016-08-25 Crystallization Method and Bioavailability

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US30211010P 2010-02-06 2010-02-06
US61/302,110 2010-02-06
US31287910P 2010-03-11 2010-03-11
US61/312,879 2010-03-11
US31850310P 2010-03-29 2010-03-29
US61/318,503 2010-03-29
US33304110P 2010-05-10 2010-05-10
US33302810P 2010-05-10 2010-05-10
US61/333,041 2010-05-10
US61/333,028 2010-05-10
US35954410P 2010-06-29 2010-06-29
US61/359,544 2010-06-29
AUPCT/US2010/043892 2010-07-30
AUPCT/US2010/043916 2010-07-30
US12/847,568 2010-07-30
US37981410P 2010-09-03 2010-09-03
US61/379,814 2010-09-03
US45577810P 2010-10-26 2010-10-26
US61/455,778 2010-10-26
PCT/US2011/023427 WO2011097269A1 (en) 2010-02-06 2011-02-02 Crystallization method and bioavailability

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/023427 Division WO2011097269A1 (en) 2009-07-31 2011-02-02 Crystallization method and bioavailability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016219653A Division AU2016219653B2 (en) 2010-02-06 2016-08-25 Crystallization Method and Bioavailability

Publications (2)

Publication Number Publication Date
AU2012216632A1 true AU2012216632A1 (en) 2012-09-20
AU2012216632B2 AU2012216632B2 (en) 2016-05-26

Family

ID=44355747

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012216632A Ceased AU2012216632B2 (en) 2010-02-06 2012-09-04 Crystallization Method and Bioavailability
AU2016219653A Ceased AU2016219653B2 (en) 2010-02-06 2016-08-25 Crystallization Method and Bioavailability

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2016219653A Ceased AU2016219653B2 (en) 2010-02-06 2016-08-25 Crystallization Method and Bioavailability

Country Status (15)

Country Link
EP (1) EP2531200B1 (en)
JP (2) JP5792748B2 (en)
AU (2) AU2012216632B2 (en)
CA (1) CA2826548A1 (en)
CY (1) CY1119192T1 (en)
DK (1) DK2531200T3 (en)
ES (1) ES2638072T3 (en)
HR (1) HRP20171201T1 (en)
HU (1) HUE035744T2 (en)
IL (1) IL221306A0 (en)
LT (1) LT2531200T (en)
PL (1) PL2531200T3 (en)
PT (1) PT2531200T (en)
SI (1) SI2531200T1 (en)
WO (1) WO2011097269A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2011014781A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
KR101813728B1 (en) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2531200B1 (en) * 2010-02-06 2017-07-12 Grünenthal GmbH Crystallization method and bioavailability
WO2012071517A2 (en) * 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102268023B (en) * 2011-08-15 2013-04-17 南京丰融化学技术有限公司 Crystal form of cefroxadine (CXD) derivative
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US20140349974A1 (en) * 2014-08-12 2014-11-27 Antecip Bioventures Ii Llc Zoledronic acid dosage forms for the treatment of pain
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
PL2849758T3 (en) * 2012-05-14 2018-08-31 Antecip Bioventures Ii Llc Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
EP2968371A4 (en) * 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
US11406713B2 (en) 2013-03-15 2022-08-09 Xortx Therapeutics, Inc. Xanthine oxidase inhibitor formulations
KR101739244B1 (en) * 2013-10-25 2017-05-23 안테씨프 바이오벤쳐스 투 엘엘씨 Compositions for oral administration of zoledronic acid or related compounds for treating disease
MX2018002627A (en) * 2015-09-18 2018-12-17 Gruenenthal Chemie Crystallization method and bioavailability.
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
KR102723076B1 (en) * 2016-12-15 2024-11-28 제이투에이치바이오텍 (주) 3-Component cocrystal
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (en) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 How to treat anxiety disorders, headache disorders and eating disorders with psilocybin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
EP1416919A1 (en) 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20040220264A1 (en) * 2003-03-17 2004-11-04 Yu Ruey J Bioavailability and improved delivery of acidic pharmaceutical drugs
ES2322592T3 (en) * 2003-07-03 2009-06-23 Teva Pharmaceutical Industries Ltd. CRYSTALLINE FORMS OF ZOLEDRONIC ACID, CRYSTAL FORMS OF SODIUM SALT OF ZOLEDRONATE, SODIUM SALT OF ZOLEDRONATE AMORFA AND PROCEDURES FOR THEIR PREPARATION.
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
JO3006B1 (en) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv Novel Lysine Salts of 4-((Phenoxy Alkyl)Thio)-Phenoxy Acetic Acid Derivatives
WO2011014781A1 (en) * 2009-07-31 2011-02-03 Thar Pharmaceuticals, Inc. Novel oral forms of a phosphonic acid derivative
KR101813728B1 (en) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 Crystallization method and bioavailability
EP2531200B1 (en) * 2010-02-06 2017-07-12 Grünenthal GmbH Crystallization method and bioavailability
WO2012071517A2 (en) * 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102070668B (en) * 2010-12-23 2013-07-24 蚌埠丰原医药科技发展有限公司 Method for preparing zoledronic acid and sodium salt thereof by utilizing phase transfer catalyst

Similar Documents

Publication Publication Date Title
IL221306A0 (en) Crystallization method and bioavailability
PL2459176T3 (en) Crystallization method and bioavailability
WO2011160196A9 (en) Multidimensional-data-organization method
EP2566246A4 (en) Carrier-aggregation-based handover method
EP2616977A4 (en) Discrete element method
EP2636463A4 (en) Forming method and forming device
EP2578380A4 (en) Preform opening crystallization method
EP2631894A4 (en) Label and method for producing same
EP2660214A4 (en) Crystallized glass
EP2637945A4 (en) Improved connecting method
EP2527939A4 (en) Safety-augmenting base and method for controlling same
EP2523570A4 (en) Carrying system
EP2600016A4 (en) Sliding member and method for producing same
EP2569068A4 (en) Separation method
EP2589656B8 (en) Gene introduction method
EP2639883A4 (en) Conductive member and method for producing same
AU2013206384B2 (en) Improved Connecting Method
AU2013204145B2 (en) Pure erlotinib
EP2634273B8 (en) Oxidation method
AU2010901800A0 (en) Membrane-Meniscus Method
HK1188348A (en) Notification method
AU2010903613A0 (en) Therapeutic method
AU2010905008A0 (en) Improved Connecting Method
AU2010904285A0 (en) Well De-Liquefying System and Method
AU2010901728A0 (en) Smelting method